Merger uncertainty and impending clinical trials for Bristol-Myers leave investors in limbo
Investors are taking a wait-and-see approach to Bristol-Myers Squibb Co., according to Credit Suisse.
Investors are taking a wait-and-see approach to Bristol-Myers Squibb Co., according to Credit Suisse.